At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.
All content for OncLive® On Air is the property of OncLive® On Air and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.
S14 Ep22: Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD
OncLive® On Air
11 minutes
1 month ago
S14 Ep22: Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD
In today’s episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.
In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with myelofibrosis who have mutations in JAK2, CALR, or MPL; the crucial roles of the JAK1, JAK2, and IRAK1 pathways in disease progression; the importance of considering JAK inhibition in eligible patients; and the challenges associated with managing cytopenic myelofibrosis.
OncLive® On Air
At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.
